Related references
Note: Only part of the references are listed.Cellular therapy for acute myeloid Leukemia - Current status and future prospects
Panupong Hansrivijit et al.
BLOOD REVIEWS (2019)
Novel amino acid-substituted diphenylpyrimidine derivatives as potent BTK inhibitors against B cell lymphoma cell lines
Changyuan Wang et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Advances in treatment formulations for acute myeloid leukemia
Thomas Briot et al.
DRUG DISCOVERY TODAY (2018)
Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma
Yang Ge et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC)
Zhendong Song et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
Design and synthesis of sulfonamide-substituted diphenylpyrimidines (SFA-DPPYs) as potent Bruton's tyrosine kinase (BTK) inhibitors with improved activity toward B-cell lymphoblastic leukemia
He Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2017)
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies
Harriet S. Walter et al.
BLOOD (2016)
Synthesis and biological evaluation of azole-diphenylpyrimidine derivatives (AzDPPYs) as potent T790M mutant form of epidermal growth factor receptor inhibitors
Zhendong Song et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis
Jin Kyun Park et al.
ARTHRITIS RESEARCH & THERAPY (2016)
Identification of Bruton's tyrosine kinase as a therapeutic target in acute myeloid leukemia
Stuart A. Rushworth et al.
BLOOD (2014)
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
Anas Younes et al.
LANCET ONCOLOGY (2014)
Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML
Lyubov Zaitseva et al.
ONCOTARGET (2014)
Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
Jan A. Burger et al.
BLOOD (2013)
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Bjoern Chapuy et al.
CANCER CELL (2013)
Ibrutinib and novel BTK inhibitors in clinical development
Akintunde Akinleye et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Annette O. Walter et al.
CANCER DISCOVERY (2013)
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies
Robert C. Rickert
NATURE REVIEWS IMMUNOLOGY (2013)
Identification of human germinal center light and dark zone cells and their relationship to human B-cell lymphomas
Gabriel D. Victora et al.
BLOOD (2012)
The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia
Martin F. M. de Rooij et al.
BLOOD (2012)
A Theory of Germinal Center B Cell Selection, Division, and Exit
Michael Meyer-Hermann et al.
CELL REPORTS (2012)
2.23 Covalent Inhibition of Btk with Clinical Development Compound AVL-292 Disrupts Signaling That Maintains the Microenvironment Necessary for Chronic Lymphocytic Leukemia Growth
E. Evans et al.
Clinical Lymphoma Myeloma & Leukemia (2011)
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
Jonathan W. Friedberg et al.
BLOOD (2010)
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis et al.
NATURE (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M
Wenjun Zhou et al.
NATURE (2009)
Share Paper
